Supernus Pharmaceuticals, Inc.
SUPNNASDAQHealthcareDrug Manufacturers - Specialty & Generic
Previous close
$45.85
−$1.60 · -3.37%
SUPN company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Hold
Wait — insufficient conviction to act
Valuation
26
Expensive
Momentum
59
Neutral
Sentiment
48
Mixed
Risk resilience
69
Moderate Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteSupernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention. Another key product is Oxtellar XR, an extended-release oxcarbazepine designed for the standalone treatment of partial-onset epileptic seizures in patients aged 6 to 17 and adults. The company also offers Qelbree, a selective norepinephrine reuptake inhibitor approved for attention-deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17. For advanced Parkinson's Disease (PD) patients, APOKYN offers acute, intermittent relief during "off" episodes of hypomobility, and XADAGO serves as an adjunctive treatment with levodopa/carbidopa for those experiencing similar off periods. Other offerings include GOCOVRI, which targets dyskinesia in PD patients, and Osmolex ER, used for Parkinson's disease and drug-induced extrapyramidal reactions in adults. MYOBLOC, a Type B toxin, is indicated for cervical dystonia and sialorrhea in adults. Beyond its commercial portfolio, Supernus is actively developing several investigational therapies. These include Qelbree (SPN-812), which has successfully completed Phase III trials for ADHD. SPN-830, a late-stage drug/device combination, aims to prevent off episodes in PD patients. SPN-817 is a novel compound in Phase I trials for severe epilepsy. SPN-820 is undergoing Phase II trials for resistant depression, and SPN-443 and SPN-446 are in earlier, preclinical stages for various CNS indications. Products are distributed through a network of pharmaceutical wholesalers, specialty pharmacies, and authorized distributors. Established in 2005, Supernus Pharmaceuticals is headquartered in Rockville, Maryland.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Jack A. Khattar
- Listed since
- May 1, 2012
- Employees
- 778
Market position
Day range
Current $45.85
52-week range
Current $45.85
- Open
- $47.76
- Previous close
- $47.45
- Volume
- 748.89K
- 0.92× average
- Average volume
- 810.47K
- Average daily volume
- Market cap
- 2.66B USD
- Beta
- 0.56
- Market reference 1
- 50-day average
- $46.6944
- -1.81% below average
- 200-day average
- $48.6278
- -5.71% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 2.72B USD
- P/E (TTM)
- -23.86×
- P/B (TTM)
- 2.58×
- P/S (TTM)
- 3.2×
- EV / EBITDA
- 63.91×
- Earnings yield
- -1.37%
- Free cash flow yield
- 1.64%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 88.07%
- Operating margin
- -13.46%
- Net margin
- -13.23%
- Return on equity
- -3.63%
- Return on assets
- -2.65%
- Return on invested capital
- -2.58%
Financial health
- Debt / equity
- 0.04×
- Current ratio
- 1.9×
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 718.95M USD | 661.82M USD | 607.52M USD | 667.24M USD | 579.78M USD |
| Cost of goods sold | 74.56M USD | 77.91M USD | 83.78M USD | 87.22M USD | 75.06M USD |
| Gross profit | 644.39M USD | 583.91M USD | 523.74M USD | 580.02M USD | 504.71M USD |
| Research and development | 106.24M USD | 108.8M USD | 91.59M USD | 74.55M USD | 90.47M USD |
| Selling, general, and administrative | 485.56M USD | 335.78M USD | 336.36M USD | 377.22M USD | 304.76M USD |
| Operating expenses | 681.25M USD | 502.25M USD | 529.01M USD | 533.89M USD | 418.69M USD |
| Interest income | 13.25M USD | 16.2M USD | 10.45M USD | 21.69M USD | 10.57M USD |
| Interest expense | — | — | 2.42M USD | 7.07M USD | 23.42M USD |
| Depreciation and amortization | 91.56M USD | 80.41M USD | 84.86M USD | 85.54M USD | 32.6M USD |
| Operating income | −36.86M USD | 81.67M USD | −5.27M USD | 46.12M USD | 86.03M USD |
| Net income | −38.55M USD | 73.87M USD | 1.32M USD | 60.71M USD | 53.42M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 73%
- 8 beats, 3 misses, 0 met estimates
- Average EPS surprise
- +54.53%
- 11 comparable reports
- Latest EPS result
- 0.54
- Estimate 0.42 · Beat by 27.81%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Rating distribution
14 ratingsSUPN news
SUPN peers
ETFs holding SUPN
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Core S&P Small-Cap ETFIJR170.48M0.15%111.19B USD0.06%$147.31+0.64%
Vanguard Morningstar Total Stock Market ETFVTI78.53M0.00%2.3T USD0.03%$378.24+0.44%
iShares Russell 2000 ETFIWM68.21M0.08%81.62B USD0.19%$299.96+0.77%
Vanguard Morningstar Small-Cap ETFVB56.56M0.03%183.4B USD0.03%$304.76+0.64%
Vanguard Morningstar Small-Cap Value ETFVBR35.93M0.05%68.3B USD0.05%$249.18+0.68%
Vanguard Extended Market ETFVXF29.78M0.03%93.7B USD0.05%$245.53+0.82%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM25.89M0.15%17.03B USD0.03%$57.28+0.61%
iShares Russell 2000 Value ETFIWN22.74M0.16%14.66B USD0.24%$224.81+0.45%iShares Core S&P Small-Cap ETFIJR- Market value
- 170.48M
- Weight
- 0.15%
- AUM
- 111.19B USD
- Expense ratio
- 0.06%
- Price / 1D
- $147.31+0.64%
Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 78.53M
- Weight
- 0.00%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $378.24+0.44%
iShares Russell 2000 ETFIWM- Market value
- 68.21M
- Weight
- 0.08%
- AUM
- 81.62B USD
- Expense ratio
- 0.19%
- Price / 1D
- $299.96+0.77%
Vanguard Morningstar Small-Cap ETFVB- Market value
- 56.56M
- Weight
- 0.03%
- AUM
- 183.4B USD
- Expense ratio
- 0.03%
- Price / 1D
- $304.76+0.64%
Vanguard Morningstar Small-Cap Value ETFVBR- Market value
- 35.93M
- Weight
- 0.05%
- AUM
- 68.3B USD
- Expense ratio
- 0.05%
- Price / 1D
- $249.18+0.68%
Vanguard Extended Market ETFVXF- Market value
- 29.78M
- Weight
- 0.03%
- AUM
- 93.7B USD
- Expense ratio
- 0.05%
- Price / 1D
- $245.53+0.82%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM- Market value
- 25.89M
- Weight
- 0.15%
- AUM
- 17.03B USD
- Expense ratio
- 0.03%
- Price / 1D
- $57.28+0.61%
iShares Russell 2000 Value ETFIWN- Market value
- 22.74M
- Weight
- 0.16%
- AUM
- 14.66B USD
- Expense ratio
- 0.24%
- Price / 1D
- $224.81+0.45%
Continue in GoAI
Research SUPNresearch.disclaimer